Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 2Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 90Lymphoid 42Other hematologic neoplasm 6Myeloid 3Dermatologic 2Classical hematology 2Sarcoma 1Genitourinary 1

Conditions

Myelodysplastic Syndromes 2Anemia 2Leukemia, Myelomonocytic, Chronic 1Leukemia 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13Cytarabine 9Dalteparin 8Rivaroxaban 7Daunorubicin 7apixaban 6Etoposide 6Methotrexate 5Idarubicin 5Heparin, Low-Molecular-Weight 5Cyclophosphamide 5emicizumab 4Tinzaparin 4Thioguanine 4Mitoxantrone 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Enoxaparin 4pegfilgrastim 3hetrombopag 3epoetin beta 3Saline Solution 3Radiotherapy 3Hydrocortisone 3Erythropoietin 3Dexamethasone 3Aspirin 3Asparaginase 3telapristone acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Lenalidomide × Classical hematology × Clear all
NCT00843882 2026-05-01

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
247 enrolled 19 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00179621 2011-04-14

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Celgene

Phase 3 Completed
205 enrolled 25 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡